Amelioration of cancer cachexia with preemptive administration of tumor necrosis factor-α blocker

Eun A Kang,1 Jong Min Park,2 Wook Jin,3 Hann Tchahe,3 Kwang An Kwon,4 and Ki Baik Hahn1,2,3,*

1CHA Cancer Prevention Research Center, CHA Bio Complex, CHA University, 330 Pangyo-dong, Bundang-gu, Seongnam 13497, Korea
2Department of Pharmacology, University of Daejeon, Daejeon, Korea
3Department of Pediatrics, Gachon University Gil Hospital, Incheon, Korea
4Department of Gastroenterology, Gachon University Gil Hospital, Incheon 21565, Korea
5Medpacto Research Institute, Medpacto, Myungdal-ro 92, Seocho-gu, Seoul 06668, Korea

(Received 8 February, 2021; Accepted 30 March, 2021; Released online in J-STAGE as advance publication 19 October, 2021)

Cancer cachexia is syndrome accompanying weight reduction, fat loss, muscle atrophy in patients with advanced cancer. Since tumor necrosis factor-α (TNF-α) played pivotal role in cancer cachexia, we hypothesized preemptive administration of TNF-α antibody might mitigate cancer cachexia. Detailed molecular mechanisms targeting muscle atrophy, cachexic inflammation, and catabolic catastrophe were explored whether TNF-α antibody can antagonize these cachexic mechanisms. Stimulated with preliminary finding human antibody, infliximab or adalimumab, significantly inhibited TNF-α as well as their signals relevant to cachexia in mice, preemptive administration of 1.5 mg/kg adalimumab was done in C-26-induced cancer cachexia. Adalimumab significantly mitigated cancer cachexia manifested with significantly lesser weight loss, leg muscle preservation, and higher survival compared to cachexia control (p<0.05). Significant ameliorating action of muscle atrophy were accompanied significant decreases of muscle-specific UPS like atrogin-1/MuRF-1, PAX-7, PCG-1α, and Mfn-2 after adalimumab (p<0.01) and significantly attenuated lipolysis with inhibition of ATGL HSL, and MMPs. Cachexic factors including IL-6 expression, serum IL-6, gp130, IL-6R, JAK2, and STAT3 were significantly inhibited with adalimumab (p<0.01). Genes implicated in cachexic inflammation like NF-kB, c-Jun/c-Fos, and MAPKs were significantly repressed, while mTOR/akt was significantly increased adalimumab (p<0.05). Conclusively, preemptive administration of adalimumab can be tried in high risk to cancer cachexia.

Key Words: cancer cachexia, C-26 cell, adalimumab, muscle atrophy, preemptive administration

Wasting of skeletal muscle and adipose tissue is a hallmark of cancer cachexia,(1) in which individual cancer cell affects host metabolism either by dysregulated metabolism or circulating factors from cancer cells. Mechanisms leading to muscle atrophy are very much complicated to abnormal immune system, nutrient impairment, sarcopenia, and organ dysfunction in addition to prominent anorexia. Ultimately, seriously reduced muscle mass is a serious symptom that can lead to death.(2–4) Besides of difficulty in treating advanced cancer causing cachexia, this complex, multi-factorial, and rather complicated nature of “cachexia” makes treatment very hard. Therefore, the treatment of cancer cachexia is a difficult disease that cannot be easily accessed due to the difficulty in recovering the underlying disease. However, if cancer cachexia can be alleviated, it can increase the quality of the patient, after which more amenable chemotherapy becomes possible, finally mitigation of cancer cachexia is important game changer for cancer patients.

As a scientific approach, many attempts have been made to inhibit cachexia either by targeting the inflammatory cytokines tumor necrosis factor-α (TNF-α) and IL-6, which are the molecular biologic mechanisms associated with the development of cancer cachexia(5–7) or adopting recent advancement of biotechnology, a number of promising agents, for instance, enobosarm as a selected androgen receptor modulator (SARM)(8) and anamorelin as a ghrelin agonist(9,10) are under Phase III studies now. Thinking of contributing pathogenesis, other agents such as infliximab as TNF-α antibody, tocilizumab as IL-6 receptor antibody(11) and bimagrumab as human antibody targeting Activin type II receptor(12) had been shown the possibility to reverse skeletal muscle. However, although some are still on clinical trial, others are already proven to be limited effect.

TNF-α played pivotal roles in causing cancer cachexia since TNF-α appears to promote muscle atrophy-associated genes such as muscle ring figure protein1 (MuRF-1) and Atrogin-1, resulting from the induction of E3 ligase genes that mediate the degradation of myofibrillar proteins by the ubiquitin proteasome pathway(13–15) and is involved in body weight homeostasis by increasing lipolysis and favoring muscle cell catabolism.(16) Therefore, trial to block cancer cachexia-associated TNF-α can be a solution, for which rather diverse approaches to block TNF-α in cancer cachexia are on progress including nutrients, anti-oxidants,(17–21) phytochemicals,(22) and recent available biologies targeting TNF-α.

Supported with our preliminary study showing that among several kinds of TNF-α antibodies such as etanercept, infliximab, infliximab biosimilar, and adalimumab, preemptive administration of adalimumab exerted highest rescuing action against cachexia models in both exploration of cellular and animal models, in this study we explored their efficacy as well as anti-cachexic mechanisms of preemptive administration of adalimumab in cancer cachexia model using colon 26 adenocarcinoma cell (C-26). Though human antibody, preliminarily we found significant inhibiting action of adalimumab human antibody in murine model.(23)

Materials and Methods

Cell culture. The cachexia-bearing C-26 is a murine colon carcinoma cell and was obtained from Cell Lines Service (no. 400156). The cells were cultured in RPMI-1640 medium supplemented with 10% heat inactivated fetal bovine serum (FBS, Sigma-Aldrich, St. Louis, MO) and 1% antibiotic/antimycotic solution (Sigma) at 37°C in a humidified atmosphere composed 5% CO₂ incubator.

*To whom correspondence should be addressed. E-mail: hahmkb@hotmail.com

doi: 10.3164/jcbn.21-21
©2022 JCBN

J. Clin. Biochem. Nutr. | March 2022 | vol. 70 | no. 2 | 117–128
Mice model of cancer cachexia. Six-week-old male Balb/c mice were allocated into one of three experimental groups: a normal group (n = 10), a cachectic C-26 adenocarcinoma bearing group (n = 10), a cachectic C-26 adenocarcinoma bearing group with 1.5 mg/kg TNF-α antibody biologics, adalimumab (n = 10). Cachectic C-26 adenocarcinoma bearing groups were shaved on the dorsal side and injected in their right flank with either 1 × 10^7 C-26 cells. Animals were handled in an accredited animal facility in accordance with the AAALAC International Animal Care Policies of CHA Bio Complex (CHA University, Pangyo, Korea) after IRB approving (#2017-0501). Before the injection of C-26 cells into mice, cells were counted using a hemocytometer and suspended in 100 μl of sterilized phosphate-buffered saline.21,22 When injecting C-26 cells to mice, we used 1 μl insulin syringe (29 gauge, BD Ultra-Fine™ needle). The recommended capacity of adalimumab to human is 80 mg in the first week. Converted to dose to be administered to mice, it was administered 1.5 mg/ml via an i.p. injection of a mixture of phosphate-buffered saline thrice in the first week of C-26 injection. All mice were monitored once every two to three days, including measuring body weight and food intake for three weeks. To check for the reduction of food intake due to anorexia, we limited feed only 100 g per each group every three days. The experiment was suspended before 4 weeks because of mortality related to cancer cachexia in this model.

Serum cytokine assays. To assess concentration of cytokine in serum, we collected the blood from mice, and separated the plasma after centrifuged at 3,000 rpm, 4°C for 30 min. IL-6 and TNF-α levels in serum were determined by a Mouse IL-6 Quantikine ELISA kit (M6000B) and a Mouse TNF-α Quantikine ELISA kit (MTA00B) all from R&D System (R&D Systems, Mineapolis, MN) according to the manufacturer’s instructions.

Reverse transcription PCR (RT-PCR). Total RNA was isolated from the leg muscle of mice using TRIzol. RNA was transcribed into cDNA using cDNA synthesis kit (TOYOBO, Osaka, Japan). The primer sequences used for RT-PCR analysis are shown in Table 1 and gylceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal standard.

Western blotting. The leg muscle tissue was finely ground with liquid nitrogen and dissolved in Cell lysis buffer to make protein lysate. All primary antibodies were diluted 1:1,000 and all secondary antibodies were diluted 1:2,000. Primary antibodies for TNF-α (Cell Signaling, Danvers, MA), tumor necrosis factor-receptor 1 (TNF-R1; Santa Cruz Biotechnology, Santa Cruz, CA), tumor necrosis factor receptor type-1 associated death domain protein (TRADD; Cell Signaling), fas-associated protein with death domain (FADD; Santa Cruz Biotechnology), interleukin-6 (IL-6, Abcam, ab6672; Darwinbio, Hanam, Korea), interleukin-6 receptor α (IL-6Rα; Santa Cruz Biotechnology), phosphor-Janus kinase 2 (p-JAK2; Cell Signaling), phosphor-signaling transducer and activator of transcription 3 (p-STAT3; Santa Cruz Biotechnology), atrogin-1 (a muscle-specific F-box protein; ECM Biosciences), muscle ring finger protein-1 (MuRF-1; Santa Cruz Biotechnology), ubiquitin (Cell Signaling), inhibitor of nuclear factor kappa-B kinase subunit beta (Ikβ); Cell Signaling), phosphor-nuclear factor of kappa light poly- peptide gene enhancer in B-cells inhibitor α (p-IκBα; Cell Signaling), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p50 (p-NF-kB p50; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), c-Jun (Santa Cruz Biotechnology), c-Fos (Cell Signaling), phosphor-extracellular signal-regulated kinases (p-ERK; Santa Cruz Biotechnology), phosphor-c-jun N-terminal kinase (p-JNK; Santa Cruz Biotechnology), phosphor-p38 mitogen-activated protein kinases (p-p38 MAPKs; Cell Signaling, #9211), phosphatidylinositol-4,5-biphosphate-3 kinase (p-Pi3K p85/p55; Cell Signaling), phosphor-Akt (Cell Signaling), phosphor-mechanistic target of rapamycin (mTOR; Cell Signaling), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology), phosphor-nuclear factor kappa-light-chain- enhancer of activated B cells p65 (p-NF-kB p65; Santa Cruz Biotechnology), phosphor-5′ AMP-activated protein kinase (p-AMPKα 1/2; Santa Cruz Biotechnology).
DeadEnd<sup>TM</sup> Fluorometric TUNEL System (G3250; Promega, Madison, WI) according to the manufacturer’s instructions.

**Zymography.** Enzymatic activities of matrix metalloproteinases (MMP)-2 and MMP-9 were assayed by gelatin zymography. Samples were electrophoresed on gelatin-containing 10% SDS-polyacrylamide gels. The gel was washed twice with washing buffer (2.5% Triton X-100, 5 mM CaCl<sub>2</sub>, 1 μM ZnCl<sub>2</sub>, 50 mM Tris-HCl, pH 7.5). This was followed by treatment with incubation buffer (1% Triton X-100, 5 mM CaCl<sub>2</sub>, 1 μM ZnCl<sub>2</sub>, 50 mM Tris-HCl, pH 7.5) and incubate for overnight at 37°C. And then, the gel was stained with Coomassie brilliant blue R-250 staining solution (BIORAD), and destained using destaining solution (methanol, acetic acid, H<sub>2</sub>O). The MMP appearing on the gel signified 72 kDa (MMP-2) and 92 kDa (MMP-9).

**Statistics.** Results are expressed as the mean ± SD. Statistical analyses of the data were performed using Graphpad (GraphPad Software, San Diego, CA) and SPSS software (ver. 12.0, Chicago, IL). All other experiments were performed on triplicated independent occasions. The data were analyzed by one-way analysis of variance (ANOVA) tests, and the statistical significance between groups was determined by Tukey’s multiple comparison test. Significance were considered at p<0.05.

**Results**

**Preemptive administration of adalimumab significantly ameliorated cancer cachexia showing lesser muscle atrophy.** In order to document whether blocking of TNF-α with adalimumab can ameliorated C-26 adenocarcinoma-induced cancer cachexia, we set three groups, normal control, C-26 group, and C-26 group treated with thrice i.p. injection of adalimumab, 1.5 mg/kg (Fig. 1A). Through preliminary study, we found C-26 adenocarcinoma injection led to mortality due to severe cancer cachexia, accompanied with significant weight loss, about 25%, around 4–5 weeks of cell transplantation. As seen in Fig. 1B, control mice showed significant loss of body weight after 3 weeks (p<0.01). However, group treated with adalimumab (Group 3) preemptively showed statistically significant difference with Group 2 in the changes of body weight (p<0.05). In this rescuing action shown in Group, neither food intake nor mean size of transplanted tumors were differed between Group 2 and Group 3, signifying cancer cachexia was not the results of decreased food intake or excess tumor growth (Fig. 1E and F). On the other hand, gross morphology of mice thigh and gastronemius muscle was quite different, signifying ameliorating effect of cancer cachexia in Group 3 was presented less muscle atrophy (p<0.01, Fig. 1C). These findings were further documented with histology of leg muscle. As seen in Fig. 1E, muscle bundles in cancer cachexia were significantly reduced, whereas muscle bundles were significantly preserved in adalimumab treated group (p<0.05). Other points of muscle degeneration, inflammation, and shrinkage were significantly ameliorated in Group 3. Further evaluation of muscle degeneration was done with immunohistochemical staining of IgG. As shown in Supplemental Fig. 1A, IgG staining was significantly increased in Group 2, while no significant change was noted in Group 3. All of these results consistently suggested muscle atrophy relevant to cancer cachexia was ameliorated in group treated with preemptive adalimumab compared to control (p<0.01).

**Inhibition of muscle-related proteasome degradation with preemptive administration of adalimumab.** The significant differences in mice leg muscle between C-26 cells-induced cancer cachexia and adalimumab pretreated cancer cachexia noted in Fig. 1 led us to investigate muscle atrophy-related genetic changes between groups. As seen in Fig. 2A, first, we have checked atrogin-1 and MuRF-1, representational genes denoting muscle atrophy in cancer cachexia, and found either atrogin-1 or MuRF-1 mRNA was significantly increased in leg muscle of C-26 adenocarcinoma-induced cancer cachexia (p<0.05). However, Group treated with adalimumab showed significant decreases in atrogin-1 and MuRF-1 mRNA expression. These changes were further confirmed with Western blot as shown in Fig. 2B. Since these genes are related to proteasomic ubiquitin ligases, we repeated blotting for ubiquitin and inhibiting ubiquitin ligases was noted in Group 3 compared to Group 2 (Fig. 2C). Also, we have confirmed Pax7 gene signifying muscle degeneration was significantly increased in Group 2, but significantly decreased in Group 3 (p<0.01, Fig. 2D). On the other hand, MyoD was significantly decreased in Group 2, but it was significantly increased in Group 3 (p<0.05, Fig. 2E). All of these muscle degeneration and atrophy was further reflected with the changes of p-AMPK, PGC-1α, and mitofusin-2 (Mfn-2) genes implicated in either mitochondrial changes or energy expenditure. As seen in Fig. 2F, adalimumab significantly ameliorated the genetic changes occurred in cancer cachexia in this matter (p<0.01).

**Adalimumab significantly blocked cancer cachexia-related TNF-α and its signaling.** According to group, the expression of TNF-α and its receptor and signaling was measured. As seen in Fig. 3A and B, the expressions of TNF-α, TNF-receptor 1, and FasL mRNA were all significantly increased in cancer cachexia group, but these expressions were significantly decreased in group treated with adalimumab (p<0.05). Also, on Western blot for TNF-α, membrane bound and soluble form), TNF-R1 as well as signaling molecules, TRADD, FADD, cleaved caspase-8, respectively, increased expressions noted in Group 2 were all significantly decreased in Group 3 (p<0.05, Fig. 3B). When we measured TNF-α levels according to group, TNF-α in sera from each group was significantly increased in Group 2, but significantly decreased in Group 3 (p<0.05, Fig. 3C). Since all of these data suggested TNF-α might contributed to cancer cachexia, whereas adalimumab significantly blocked cachexie effect of TNF-α, we further hypothesized apoptosis in muscle might be differ between groups. As seen in Fig. 3D, apoptotic index in mice leg muscle was significantly increased in Group 2, but significantly decreased in Group 3 (p<0.01).

**Adalimumab significantly attenuated cancer cachexia-related lipolysis and protease.** As much as muscle atrophy, lipolysis is a prominent phenomenon noted in cancer cachexia. As seen in Fig. 4A, ATGL and HSL expressions were significantly increased in adipose tissues obtained from Group 2, but significantly attenuated in group treated with adalimumab (p<0.05). These findings were further reflected with changes in fatty acid synthase (FAS) and Srebp-1 (Fig. 4B). Combined with these muscle degradation and lipolysis, systemic activation of MPs further aggravated cachexia. In this matter, when we checked MMP-2 and MMP-9 mRNA, these MMPs were significantly decreased with adalimumab administration (p<0.05). The activity of MMPs was measured with zymography. As seen in Fig. 4D, preemptive adalimumab significantly attenuated cachexia-induced MMPs, especially MMP-9.

**Block of IL-6 driven cancer cachexia by adalimumab.** As much as surges of TNF-α observed in cancer cachexia, IL-6 and its signaling mechanism had been implicated in its pathogenesis. As shown in Fig. 5A, the expressions of IL-6, IL-6R, and gp130 mRNA were significantly increased in Group 2, but these expressions were significantly decreased in Group 3. On Western blot for these IL-6 and its receptor, same finding was noted (Fig. 5B). ELISA levels of IL-6 were also significantly increased in sera of Group 2, but statistically significantly decreased in Group 3 (p<0.05, Fig. 5C). Also, when explored about IL-6 signaling, the expressions of phosphorylated JAK2 and STAT3 were significantly increased in Group 2, but significantly decreased in Group 3 (p<0.05, Fig. 5D).

*See online. https://doi.org/10.3164/jcbn.21-21
Fig. 1. Efficacy of i.p. administered adalimumab, 1.5 mg/kg, on mitigating C26 adenocarcinoma-induced cancer cachexia. (A) Schematic protocol for experiment Balb/c mice were administered with $1 \times 10^7$ cells/ml on side of abdomen. Three times intraperitoneal injections of adalimumab in the first week of C-26 cells injection were given on the first week of cell administration. (B) Daily measurement of body weight according to group. Significant difference of whole body weight was noted after 2 weeks of C-26 cells injection ($p<0.01$). (C) Representational photo showing both thigh and leg muscle. Using imaging analysis, individual muscle mass of leg was measured and averaged according to group. Statistically significant decreases in muscle mass were noted in Group 2 control ($p<0.01$). (D) Histopathology of leg gastrocnemius muscle. The pathological scores including muscle bundle size, presence of inflammation, and degree of muscle change were shown according to group, ×40 magnification. (E) Mean amounts of daily food intake were averaged according to group. No significant difference in amounts of pellet diet was noted between groups. (F) The mean size and volume of resected C-26 adenocarcinoma after 3 weeks. No significance in tumorigenesis was noted between groups.
Fig. 2. Muscle related gene changes according to group. (A) RT-PCR for atrogin-1 and MuRF-1 mRNA. (B) Western blot for atrogin-1 and MuRF-1. (C) Western blot for proteasome ubiquitin ligases. (D) Western blot for Pax7, muscle transcription factor. (E) Western blot for MyoD for muscle regeneration. (F) Western blot for p-AMPK, PGC-1α, and Mfn-2.

**Signaling molecules principally implicated in cancer cachexia progression including cachexic inflammation and catabolism.** All gross as well as underlying molecular genes implicated in cancer cachexia were consistently ameliorated with TNF-α antibody. Therefore, since we have the curiosity whether adalimumab also influenced on the changes of signaling molecules. We proceed to compare NF-κB, AP-1, MAPK, and mTOR signaling molecules and found that significant inhibition of NF-κB transcription factors was noted in Group 3 (p<0.01, Fig. 6A), significant decreases in either c-Jun or c-Fos (p<0.05, Fig. 6B), and inhibition of MAPKs such as ERK1/2, JNK, and p38 (p<0.05, Fig. 6C). On the other hand, repressed PISK, AKT, and mTOR essential in regeneration against cachexia was all significantly restored in Group 3 (p<0.05, Fig. 6D).

**Discussion**

In this study, we have documented the possibility of adalimumab, biologics consisted of humanized TNF-α antibody actively prescribed for the treatment of inflammatory bowel disease, rheumatic arthritis, and psoriasis, as ameliorating agent for cancer cachexia. Though reported earlier that similar biologics, infliximab or etanercept, failed in clinical trial in advanced patients suffering from lung cancer, we dare to conclude that adalimumab can be tried for rescuing from troublesome cancer cachexia in preemptive consideration rather than post-event treatment in patients with high risk and patients with invasive cancer. As summarized in Fig. 7, all the molecular changes implicated in the pathogenesis of cancer cachexia, consisting of muscle atrophy, cachexic inflammation, and catabolic catastrophe, are all significantly ameliorated with earlier three times preemptive administration of adalimumab. Though the consensus when to administer, how much dosing, and how long to administer is still not determined, from our current study, earlier preemptive intervention of adalimumab should be chosen to attenuate the molecular, pathogenic, and contributing events of cancer cachexia. Though no overt biomarker to predict cancer cachexia is available yet, we inferred earlier intervention to mitigate possible mechanisms of cancer cachexia in patients carrying higher risk of cancer cachexia due to invasive nature should be considered. Though required further clinical trial, we dare to stress that preemptive administration of
Fig. 3. Assay for the changes of TNF-α and its receptor including signal molecules and TUNEL for apoptosis. (A) RT-PCR for TNF-α, TNF-R1, and FasL mRNA. (B) Western blot for TNF-α, membranous form and soluble form, TNF-R1, TRADD, FADD, and cleaved caspase-8. (C) ELISA for sera levels of TNF-α according to group. (D) TUNEL to assess apoptosis. Apoptotic index was shown according to group, ×40 magnification.
mRNA involved in lipolysis and protease. (A) Western blot for ATGL and HSL. (B) RT-PCR for MMP-2 and MMP-9 mRNA. (C) Zymography for MMP activities.

TNF-α antibody can rescue from cancer cachexia in patients suffering from advanced stage of cancer vulnerable to cancer cachexia.

Since muscle wasting occurs systemically in older people as either a physiological response to malnutrition or one of manifestations in many diseases such as chronic obstructive pulmonary disorder, diabetes mellitus, chronic renal failure, heart failure, sepsis, burns as well as advanced cancer, the loss of muscle mass and strength developed first, then led to vicious circle of further losses of muscle function, aggravated to reduced quality of life and mortality, in which excess protein breakdown and reduced protein synthesis prevails. Therefore, therapeutic approach targets either to compensate inhibiting protein breakdown or to increase protein synthesis should be provided. Though either nutrient enrichment or optimal exercise might be a basic approach to prevent or slow muscle atrophy, the reality is not so easy because of cachexia developed after advanced underlying chronic disease and wasting condition not responsive to general treatment. This is why preemptive intervention should be considered. Recent advancement in either enhanced understanding of cellular mechanisms regulating protein balance in muscle/fat, specifically cytokines, or the feasible application of several promising therapeutic agents to combat muscle wasting might raise the possibility to prevent or mitigate cachexia. Nobody guess that exercise might be the only validated treatment, reduces various types of atrophy, but it can’t be a practical option for bed-ridden, frail, sarcopenic patients suffering advanced cancer. Therefore, there is unmet medical need to develop drugs or intervention to increase muscle regeneration or inhibit atrophy. In this matter, research on exploring the molecular mechanisms underlying muscle atrophy during cancer cachexia has expanded in the last years to discover several potential therapeutic targets. In detail, agents increasing the levels of PGC-1α, transcription factor jun-B (JUNB) or SIRT1 to slow muscle wasting in various catabolic status, myostatin to antagonize “myostatin - activin A - GDF-11“ signaling as an autocrine factor limiting muscle size, IGF-1 analogues, ghrelin mimetic, β2-adrenoreceptor agonists and androgen/selective androgen receptor modulators are under active development. With substantial progress, some such as myostatin and activin A antagonists are under high expectation, but future use of these agents is still under expectation with warranty of ultimate safety.

In the current study, under the hope to develop “safe and effective multi-mechanistic anti-cachexia drug”, using RNAseq to discover critical path to cancer cachexia in C-26 adenocarcinoma model, we reached to document the application of biologics targeting “TNF-α” and “IL-6”. Also supported with our investigation that infliximab or adalimumab could improve wasting symptoms in pediatric Crohn’s disease and strong data showing wasting condition reflecting the severity of in inflammatory bowel disease much better than current inflammation biomarkers such as CRP, ESR, and fecal calprotectin led us to investigate TNF-α antibody for ameliorating action against cachexia. Before our investigation, though Jatoi et al.(36) tried placebo-controlled double blinded trial of etanercept for 63 patients with incurable malignancy having weight loss of >2.27 kg over 2 months and/or daily intake of <20 calories/kg, etanercept did not palliate cancer anorexia/weight loss syndrome. Also, 3 years later, additional study placebo controlled double-blind trial of infliximab for cancer associated weight loss in non-small cell lung cancer patients was done by same investigator, Jatoi et al., but studies were suspended due to no inhibition of muscle wasting accompanied with increased fatigue and inferior global quality of
life, deeming our expectation. In spite of these negative trials, we inferred they just explored the therapeutic efficacy of TNF-α antibody in very late stage and evaluated cross-sectional effects after TNF-α antibody, that is, too late stage and too narrow parameter. Before our study, we have tried all three TNF-α antibodies, etanercept, infliximab and remisima as infliximab biosimilar, and adalimumab, highest inhibition of muscle atrophy as well as general condition was noted in group administered with adalimumab preemptively. As noted in our study, preemptive administration of adalimumab has achieved either quantitative (muscle mass and weight preservation) or qualitative (low mortality with high quality of life) advantages over C-26 adenocarcinoma-induced severe wasting condition. In another model showing wasting condition, APC^Min^-^/+^ mice developing intestinal polypsis due to APC gene mutation and LLC cell-induced cachexia model, similar outcome was obtained, preemptive administration of adalimumab significantly rescued wasting condition in accordant with mitigated polypsis and ameliorated muscle atrophy (data not shown). Hence, the common features drawn from our trial with adalimumab were that they did not change either food intake or tumor growth, but significantly amelioration of cachexia. Conclusively, although previous two studies by Jatoi et al.,(34,35) concluding TNF-α antibodies were not effective against cancer cachexia, the limitations of their clinical studies were that they only focused on appetite, weight gain, and tumor staging under intervention during obscure stage of cancer, simply mentioned as advanced malignancy was included.

In the current study, adalimumab administration played concerted roles in ameliorating cancer cachexia through limiting cachexia-associated inflammation, inhibiting muscle atrophy, and mitigating other catabolic catastrophe as summarized in Fig. 7. Interestingly either food intake or tumor growth was not influenced at all relevant to cachexia improvement. IL-6 and interferon-γ in addition to TNF-α led to increased ubiquitin dependent proteolysis and resulted in increased degradation of skeletal muscle. Since the ubiquitin proteasome system (UPS), an ATP-dependent proteolytic system mediating the degradation of target proteins by the conjugation of ubiquitin molecules is especially the main regulatory mechanism of protein degradation in skeletal muscle, in detail, two muscle specific E3 ubiquitin ligase, MuRF-1 and muscle atrophy F-box, MAIFbx/atrogen-1, have been shown to be implicated in the regulation of skeletal muscle atrophy, up-regulated during cancer cachexia and regarded as molecular target for treating cancer cachexia.(38,39) As presented in Fig. 2A-C, atrogen-1 and MuRF-1 are significantly elevated in leg muscles during cancer cachexia progression, lesser in group treated with preemptive adalimumab. In addition to these UPS, increased expressions of Pax7, transcription factor for muscle regeneration, contributed to compensate atrophy,(40,41) PGC-1α,(42,43) and Mfn-2(44) noted in cancer cachexia were significantly decreased with adalimumab administration, validating anti-cachexic effect of adalimumab (Fig. 2D and F).

In addition to muscle changes, near loss of intestinal or su-
cutaneous or genital fat is additional prominent finding noted in cancer cachexia mostly due to increased lipases and lipid droplet-associated protein expression, showing adipose tissue lipolysis and deranged energy metabolism during cancer cachexia.\(^{(45-47)}\) In our study, over-expressions of ATGL and HSL noted in cancer cachexia significantly decreased with preemptive adalimumab. These findings were further featured with the changes of fat related transcription factor, Srebp-1. Usually, the pathological features of adipose tissue existing in cancer cachexia are shrunken, heterozygous sized, and fibrotic adipocytes,\(^{(48)}\) so called ultrastructure of 'slimmed' adipocytes. However, in our study, the expressions of FAS and Srebp-1c were increased in cancer cachexia, whereas significantly decreased with adalimumab, suggesting effective compensatory mechanisms to lipolysis were intervened to cover cancer cachexia with adalimumab. However, further detailed measurements including content of C/EBP-α, acetyl CoA carboxylase, stearoyl CoA desaturase-1, and glycerol-3-phosphate acyl transferase should be followed for full explanation regarding anti-lipolysis of adalimumab.\(^{(49)}\) Furthermore, significant inhibition of MMP-9 with adalimumab seems to be also very contributing action against either cancer cachexia, since MMP expressions were prominently changed during either cancer cachexia or cardiac muscle atrophy.\(^{(50)}\)

All of these beneficial contributions of adalimumab should be imposed with pertinent modulation of signal transduction regarding metabolism advantages. First, encouraging mTOR and AKT signaling to overcome sarcopenia with adalimumab, silver

**Fig. 6.** Expression levels of transcription factor NF-κB, acute phase response gene, MAPKs, and genes involved in cell growth. (A) Western blot for Ikβ, p-IκBα, p-NF-κB p50, and p-NF-κB p65. (B) Western blot for c-Jun and c-Fos. (C) Western blot for p-ERK1/2, p-JNK, and p-p38. (D) Western blot for PTEN, p-PI3K, p-AKT, and p-mTOR.
linings on the horizon by Ebner and Haehling.\(^\text{51}\) is recommended since long-term use of mTOR inhibitors led to a marked loss of muscle mass.\(^\text{52}\) As summarized by several investigators\(^\text{53-55}\) and ours in the current study, molecular substrates and mechanisms underlying the dysregulation of skeletal muscle synthesis and degradation included proinflammatory cytokines such as TNF-\(\alpha\), IL-1, IL-6 and related signaling transduction systems such as NF-\(\kappa\)B, MAPKs, acute phase reactants, and myostatin-activin-SMAD pathways\(^\text{54}\). Though not studied in the current investigation, metastatic cancer to bone increased TGF-\(\beta\) and related myostatin contributed muscle atrophy via FOXO activation. However, though still under clinical trial, myostatin inhibition did not show anticipating outcome.\(^\text{55}\)

Conclusively, even though mentioned above that clinical trials of similar TNF-\(\alpha\) antibodies, etanercept or infliximab, did not achieve any improvement of cancer cachexia, we believe future trial with adalimumab covering the underlying pathogenic events of cancer cachexia with significant improvement of each catabolic catastrophe, cachexic inflammation, and muscle atrophy should be planned to ameliorate cancer cachexia through well-designed RCT. Quite Similar to our previous publication,\(^\text{56}\) important lesson from our preclinical trial under the concept of preemption that rather than patients with far advanced stage, preemptive administration of adalimumab might be considered under the pertinent biomarkers or clinical predictive findings suggestive of being cancer cachexia since correcting cachexic mechanisms rather than removing cachexic conditions seem to be practical.

Acknowledgments

This work was supported by Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries (IPET) through High Value-added Food Technology Development Program, funded by Ministry of Agriculture, Food and Rural Affairs (MAFRA) (116015-03-1-CG00) and granting from California Walnut Commission.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ATF6         | ER stress transcription factor activating transcription factor 6 |
| ATGL         | adipose triglyceride lipase |
| C-26         | colon adenocarcinoma 26 |
| FASN         | fatty acid synthase |
| FOXO         | members of the class O of forkhead box transcription factors |
| HSL          | hormone sensitive lipase |
| IL-6/IL-6R   | interleukin-6/interleukin-6 receptor |
| JAK2         | Janus kinase 2 |
| MAPK         | mitogen activated protein kinase |
| MMPs         | matrix metalloproteinases |
| Mfn-2        | mitofusin-2 |
| MMPs         | matrix metalloproteinases |
| mTOR         | mammalian target of rapamycin |
| MuRF-1       | muscle ring figure protein I |
| NF-\(\kappa\)B | nuclear factor-kappa B |
| Pax-7        | paired protein-7 |
| PCG-1\(\alpha\) | peroxisome proliferator activator receptor gamma coactivator protein-1 alpha |
Conflict of Interest

No potential conflicts of interest were disclosed.
Bing C, Russell S, Becket E, et al. Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumor-bearing mice. Br J Cancer 2006; 95: 1028–1037.

Inadera H, Nagai S, Dong HY, Matsushima K. Molecular analysis of lipid-depleting factor in a colon-26-inoculated cancer cachexia model. Int J Cancer 2002; 101: 37–45.

Devine RD, Bicer S, Reiser PJ, Velten M, Wold LE. Metalloproteinase expression is altered in cardiac and skeletal muscle in cancer cachexia. Am J Physiol Heart Circ Physiol 2015; 309: H685–H691.

Ebner N, von Haehling S. Silver linings on the horizon: highlights from the 10th Cachexia Conference. J Cachexia Sarcopenia Muscle 2018; 9: 176–182.

Gyawali B, Shimokata T, Honda K, et al. Muscle wasting associated with the long-term use of mTOR inhibitors. Mol Clin Oncol 2016; 5: 641–646.

Guttridge DC. A TGF-β pathway associated with cancer cachexia. Nat Med 2015; 21: 1248–1249.

An JM, Kang EA, Han YM, et al. Dietary intake of probiotic kimchi ameliorates IL-6-driven cancer cachexia. J Clin Biochem Nutr 2019; 65: 109–117.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/).